Provexis Regulatory News (PXS)

2 April 2012

Provexis plc

Directorate change

Provexis plc ("Provexis" or the "Company"), the life-science business that develops, licenses and markets scientifically-proven functional food and sports nutrition technologies, is delighted to announce the appointment of John Clarke, the highly experienced former GlaxoSmithKline ("GSK") senior executive, as a Non-executive Director.

Mr Clarke has extensive experience of the functional food and sports nutrition sectors, having worked at GSK for more than 35 years. In 2006 he was appointed global President of GSK Consumer Healthcare, a position from which he recently stepped down. Under his leadership, GSK Consumer Healthcare was the fastest-growing business in the industry throughout the period, growing by 60% and reaching sales of £5 billion despite recessionary environments in the majority of the business' markets. The business added £2 billion in turnover from 2006. Mr Clarke was responsible for the Lucozade brand including strategy, innovation programme, portfolio and global expansion for 15 years from 1996 to 2011. Lucozade achieved growth of 13% CAGR through the 1996 -2011 period, with sales now approaching 400 million pounds.

Mr Clarke's appointment at Provexis is effective from 1 April 2012.

John Clarke commented: "I am delighted to be joining the Board of Provexis. I believe the recently acquired Science in Sport brand has significant growth potential and I look forward to assisting the Company in achieving its true potential. I am particularly impressed by the Company's scientific and regulatory expertise, which has underpinned the development of the Fruitflow® heart-health technology, and which will assist also in driving innovation for Science in Sport."

Dawson Buck, Chairman of Provexis, said: "John Clarke is recognised as an outstanding leader in the global consumer healthcare industry and I am therefore delighted that he has decided to join Provexis at this exciting stage in our development. His proven success and in-depth knowledge in the consumer healthcare and sports nutrition sectors will be an important factor as we take Provexis to its next level of development."

Additional information:

John Milne Clarke, age 62 years, holds no shares in Provexis. He was President of GlaxoSmithKline Worldwide Consumer Healthcare, and was a member of GlaxoSmithKline plc Corporate Executive Team until March 2012. Mr Clarke is the non-executive Chairman of Futura Medical plc.

There are no further disclosures to be made in relation to Mr Clarke under Schedule 2(g) and (i) of the AIM rules.

-ends-

Enquiries: